Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions

DESTINATION 2 is a multi-centre randomised trial treating intermediate risk localised prostate cancer with 2 fraction Stereotactic Body Radiotherapy (SBRT). All radiotherapy will be delivered in two fractions (sessions) on an MR Linac using daily adaptation. Men will either receive uniform dose radiotherapy or de-escalated dose radiotherapy. The primary endpoint is acute GU CTCAE v5 grade 2+ toxicity. It will also look at late toxicity, patient-reported outcome measures and PSA control.

Trial Details

NCT ID
NCT06638541
Phase
NA
Sponsor
Royal Marsden NHS Foundation Trust
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Prostate radical radiotherapy
Locations (sample)
  • Toronto, Canada|43.65333,-79.38389
  • Manchester, United Kingdom|53.48095,-2.23743
  • Sutton, United Kingdom|51.35,-0.2

Key Eligibility Criteria

  • Men aged ≥18 years
  • Histological confirmation of prostate adenocarcinoma requiring radical radiotherapy
  • Gleason score 3+3, 3+4 or 4+3 (Grade groups (GG) 1, 2 or 3)
  • MRI stage T3a or less (as staged by AJCC TNM 2018). MRI must be performed within a year of randomisation

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →